Effects of Delta-9-THC and Iomazenil in Healthy Humans

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-02-11

Study Completion Date

2013-02-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study aims to examine the combined effects of delta-9-tetrahydrocannabinol (∆-9-THC or THC) and iomazenil on thinking, perception, mood, memory, attention, and electrical activity of the brain (EEG). THC is the active ingredient of marijuana, cannabis, "ganja", or "pot". Iomazenil is a drug that works opposite to drugs like valium. The purpose of this study is to determine whether the administration of iomazenil will alter the effects of THC.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans

NCT06058702

Schizophrenia Cannabis Use Disorder

RECRUITING PHASE1

Does Cannabidiol Attenuate the Acute Effects of ∆9-tetrahydrocannabinol Intoxication in Individuals Diagnosed With Schizophrenia? A Double-blind, Randomised, Placebo-controlled Experimental Study

NCT04605393

Schizophrenia Cannabis Use

COMPLETED NA

Cannabidiol Treatment in Patients With Early Psychosis

NCT02504151

Schizophrenia Schizoaffective Disorder

COMPLETED PHASE2

Probing the Cannabinoid System in Individuals With a Family History of Psychosis

NCT02102113

Psychosis Cannabis Use THC +2 more

ACTIVE_NOT_RECRUITING EARLY_PHASE1

Cannabis and Schizophrenia: Self-Medication and Agonist Treatment

NCT00946348

Schizophrenia Dual Diagnosis Schizoaffective Disorder +2 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia Mental Disorders Psychotic Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

THC and Iomazenil

* Iomazenil: 3.7 μg/kg intravenously over 10 minutes
* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or "joint". It is administered intravenously for 10 minutes

Group Type ACTIVE_COMPARATOR

THC and Iomazenil

Intervention Type DRUG

* Iomazenil: 3.7 μg/kg intravenously over 10 minutes
* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or "joint". It is administered intravenously for 10 minutes.

Placebo

Control: small amount of alcohol intravenous (quarter teaspoon), with no THC

Group Type PLACEBO_COMPARATOR

Placebo (control)

Intervention Type DRUG

Control: small amount of alcohol intravenous (quarter teaspoon), with no THC

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

THC and Iomazenil

* Iomazenil: 3.7 μg/kg intravenously over 10 minutes
* Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or "joint". It is administered intravenously for 10 minutes.

Intervention Type DRUG